Pancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Pancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Results: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
Phase 2 trial results for nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lun…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors [Phase 1]
Phase 1 trial evaluating addition of M3814 (Peposertib) to Lutetium-177 dotatate for pancreatic neuroendocrine tumors; study currently activ…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors [Phase 1]
A Phase 1 clinical trial evaluating a gene-modified immune cell therapy after a conditioning regimen for metastatic melanoma and other metas…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors [Phase 1]
Phase 1 trial of a survivin long peptide vaccine in patients with metastatic neuroendocrine tumors has completed, assessing safety and preli…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [EARLY_Phase 1]
Early-phase safety study of the radiopharmaceutical 212Pb-VMT-alpha-NET in patients with neuroendocrine tumors is active but not currently r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial update of sapanisertib with ziv-aflibercept in patients with recurrent, metastatic, or unresectable solid tumors, including fi…
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours [Phase 2]
Phase 2 clinical trial evaluating 68Ga-labeled octreotide analogue PET imaging in duodenal and pancreatic neuroendocrine tumors. The study s…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor [Phase 3]
Phase 3 trial evaluating sequential therapy with Everolimus followed by STZ-5FU in advanced pancreatic neuroendocrine tumors has completed a…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy [Phase 2]
Phase 2 trial evaluating the effect of proton pump inhibitors on postoperative recovery after pancreaticoduodenectomy; the study was termina…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II [Phase 2]
This document reports the completion of a randomized Phase II trial comparing peptide receptor radionuclide therapy with Lutetium-177 dotata…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China [Phase 4]
Phase IV study evaluating the safety and efficacy of everolimus in adults with progressive pancreatic neuroendocrine tumors in China has com…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Neoadjuvant PRRT With Y-90-DOTATOC in pNET [Phase 2]
Phase 2 neoadjuvant radiopharmaceutical therapy with Y-90-DOTATOC for pancreatic neuroendocrine tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction [NA]
A completed clinical trial evaluating a minimally invasive pancreatic enucleation technique with exposure and repair/reconstruction of the m…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Pancreatic Fistula After Minimally Invasive Enucleation
Clinical trial update on completion of a study evaluating pancreatic fistula after minimally invasive enucleation for benign pancreatic tumo…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors [Phase 3]
Phase 3 trial evaluating cabozantinib in patients with advanced pancreatic neuroendocrine tumors and carcinoid tumors; results have been pos…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors [Phase 3]
Phase 3 trial evaluating cabozantinib in advanced pancreatic neuroendocrine and carcinoid tumors; ACTIVE_NOT_RECRUITING with results posted …
-
CLINICAL_TRIALS trial_result · 2024-08-26Clinical Trial Update: Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients [NA]
A completed clinical trial from Yonsei University evaluated whether oral protein supplements improve nutrition and quality of life after pan…
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma [Phase 1]
DCR-MYC, an investigational therapy, was evaluated in a Phase I multicenter dose-escalation study in patients with solid tumors, multiple my…
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
A clinical trial update reports safety and efficacy data for sunitinib in Chinese patients with progressive, advanced or metastatic well-dif…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
This clinical trial update reports the completion of studies examining biomarkers of angiogenesis in renal cell carcinoma and neuroendocrine…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: OPALINE : A Study Of Morbidity And Mortality At 2 Years
Clinical trial update for OPALINE reports morbidity and mortality outcomes at 2 years in well-differentiated, progressive pancreatic neuroen…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors [Phase 2]
Phase 2 clinical trial update for cabozantinib in advanced pancreatic neuroendocrine tumors and carcinoid tumors has completed with results …
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET [Phase 2]
Phase 2 trial update on neoadjuvant PRRT with 177Lu-DOTATATE followed by surgery for resectable pancreatic neuroendocrine tumors (PanNET).
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors [Phase 3]
Phase III study results for surufatinib in advanced pancreatic neuroendocrine tumors completed.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating temozolomide with or without capecitabine in advanced pancreatic neuroendocrine tumors, including subtypes such as …